Division of Breast and Melanoma Surgical Oncology, Department of Surgery, Mayo Clinic, Rochester, MN, USA.
Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Ann Surg Oncol. 2022 Aug;29(8):4740-4749. doi: 10.1245/s10434-022-11759-y. Epub 2022 Apr 22.
Management of the axilla in patients with cT1-2N0 breast cancer with one or two positive (+) sentinel lymph nodes (SLNs) is often debated, especially in patients undergoing mastectomy. In 2018, the National Cancer Database (NCDB) began collecting the number of +SLNs, enabling identification of patients with one or two +SLNs for the first time.
From the 2018 NCDB participant user file (PUF), all cT1-2N0M0 patients with one or two +SLNs were identified. The rates of completion axillary lymph node dissection (cALND) after breast-conserving surgery (BCS) and mastectomy were determined, and logistic regression was used to assess factors associated with cALND.
Of 10,531 patients with one or two +SLNs, cALND was performed in 807/6498 (12.4%) BCS patients and 1845/4033 (45.7%) mastectomy patients (p < 0.001). Factors associated with cALND in BCS were cT2 versus cT1 (16.0% versus 11.1%, p < 0.001), two versus one positive SLN (20.7% versus 10.8%, p < 0.001), and higher tumor grade (grade 3: 15.4% versus grade 1-2: 11.7%, p = 0.002). Factors associated with cALND among mastectomy were cT2 versus cT1 (48.2% versus 43.7%, p = 0.004), two versus one positive SLN (56.6% versus 42.8%, p < 0.001), younger age (age < 50 years: 49.0%, age 50+ years: 44.1%, p = 0.004), and Hispanic ethnicity (55.7% versus 45.1%, p = 0.001). After adjusting for pN category, adjuvant radiation was significantly less likely after mastectomy if cALND was performed (odds ratio (OR) 0.51, p < 0.001).
Omission of cALND with one or two +SLNs in BCS is common. Deescalation of axillary therapy in mastectomy is slower, with a cALND rate of 45.7% in 2018. With the recent updates to the National Cancer Care Network (NCCN) guidelines, we anticipate continued deescalation of axillary therapy in mastectomy patients.
对于腋窝有 1 个或 2 个阳性(+)前哨淋巴结(SLN)的 cT1-2N0 乳腺癌患者的管理,尤其是接受乳房切除术的患者,存在很多争议。2018 年,国家癌症数据库(NCDB)开始收集+SLN 的数量,首次能够识别出腋窝有 1 个或 2 个+SLN 的患者。
从 2018 年 NCDB 参与者用户文件(PUF)中,确定所有腋窝有 1 个或 2 个+SLN 的 cT1-2N0M0 患者。确定乳房保留手术后(BCS)和乳房切除术后完成辅助腋窝淋巴结清扫术(cALND)的比率,并使用逻辑回归评估与 cALND 相关的因素。
在 10531 例腋窝有 1 个或 2 个+SLN 的患者中,807/6498(12.4%)例 BCS 患者和 1845/4033(45.7%)例乳房切除术患者行 cALND(p<0.001)。BCS 中与 cALND 相关的因素包括 cT2 与 cT1(16.0%比 11.1%,p<0.001)、两个与一个阳性 SLN(20.7%比 10.8%,p<0.001)和更高的肿瘤分级(3 级:15.4%比 1-2 级:11.7%,p=0.002)。乳房切除术中与 cALND 相关的因素包括 cT2 与 cT1(48.2%比 43.7%,p=0.004)、两个与一个阳性 SLN(56.6%比 42.8%,p<0.001)、年龄较小(<50 岁:49.0%,50 岁及以上:44.1%,p=0.004)和西班牙裔(55.7%比 45.1%,p=0.001)。调整 pN 分类后,如果行 cALND,乳房切除术的辅助放疗明显更不可能(比值比(OR)0.51,p<0.001)。
腋窝有 1 个或 2 个+SLN 的 BCS 患者常遗漏 cALND。乳房切除术的腋窝治疗降级较慢,2018 年 cALND 率为 45.7%。随着国家癌症护理网络(NCCN)指南的最新更新,我们预计乳房切除术患者的腋窝治疗将继续降级。